Lynch named Third Rock entrepreneur-in-residence
Life sciences-focused Third Rock Ventures  LLC has added Daniel S. Lynch, former CEO of ImClone Systems Inc., as entrepreneur-in-residence at the venture capital firm.
Lynch most recently has been serving as executive chairman  of both Avila Therapeutics Inc. and Stromedix Inc. At ImClone, where he also held the CFO post in addition to the CEO role, he led the FDA approval of cancer treatment Erbitux and negotiated partnership with Bristol-Myers Squibb. Prior to ImClone, he held financial positions at Bristol-Myers Squibb. He now is a board member of bluebird bio, a portfolio company of Third Rock Ventures.